| Summary of related party |
| | | | | | Related Parties | | Relationship | Dr. Anil Diwan | | President and Executive Chairman, significant stockholder through his ownership of TheraCour, and Director | | | | TheraCour Pharma, Inc. (“TheraCour”) | | An entity owned and controlled by Dr. Anil Diwan | | | | Karveer Meditech Private Limited (“KMPL”) | | An entity where Dr. Anil Diwan is a passive investor and advisor without operating control | | | | Meeta Vyas | | Chief Financial Officer, does not claim beneficial ownership of stock through her husband, Dr. Anil Diwan |
| | | | | | | | | | | | | | | | For the three months ended | | | September 30, | | September 30, | | | 2026 | | 2025 | Property and Equipment | | | | | | | | | | | | | | During the reporting period, TheraCour acquired property and equipment on behalf of the Company from third party vendors and transferred such property and equipment, at cost to the Company | | $ | — | | $ | 6,250 |
| | | | | | | | | | | | | | | | As of | | | September 30, | | June 30, | | | 2026 | | 2026 | Accounts Payable – Related Party-TheraCour | | | | | | | | | | | | | | Pursuant to an Exclusive License Agreement entered into with TheraCour, the Company was granted exclusive licenses for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. On November 1, 2019, the Company entered into the VZV Licensing Agreement with TheraCour. In consideration for obtaining these exclusive licenses it was agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of certain direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) the Company will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on the Company’s behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour and; (4) to pay an advance payment equal to twice the amount of the previous months invoice to be applied as a prepayment towards expenses. On February 12, 2024, TheraCour and the Company agreed to suspend the license requirement for a two month advance until the Company raises sufficient capital, therefore there was no advance offset of the accounts payable due TheraCour at September 30, 2026 and at June 30, 2026. | | $ | 704,441 | | $ | 828,577 |
| | | | | | | | | | | | | | | | For the three months ended | | | September 30, | | September 30, | | | 2026 | | 2025 | Research and Development Costs - Related Party | | | | | | | | | | | | | | Development fees and other costs charged by TheraCour pursuant to the license agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2026 and September 30, 2025. | | $ | 549,606 | | $ | 539,522 |
Clinical Trial Costs - Related Party | | | | | | | | | | | | | | | | For the three months Ended | | | September 30, | | September 30, | | | 2026 | | 2025 | Clinical trial related and other costs were charged by KMPL pursuant to the license agreement between the Company and KMPL for the clinical trial related costs that have been incurred for Phase 1a/1b clinical trials in India as of June 30, 2026. On May 26, 2026 KMPL invoiced and the Company paid an advance payment under the Covid Phase 1 Budget provisions of $299,130. $43,610 was expensed to Clinical Trial Cost – Related Party at June 30, 2026. The remainder of $255,520 has been recorded as a prepaid expense. There were no additional expenditures for the three months ended September 30, 2026 chargeable to the prepaid funds. Additional charges may follow upon reconciliation of the budgetary provisions and actual expenditures. | | $ | — | | $ | — |
| | | | | | | | | | | | | | | | As of | | | September 30, | | June 30, | | | 2026 | | 2026 | Clinical Trial Costs Accrued - Related Party | | | | | | | | | | | | | | Clinical trial costs accrued-related party includes expenses for clinical trial expenses of $226,415, and for fees due to KMPL as Clinical Trial Manager for the Mpox Phase II clinical trial of $306,015. Additionally, accrued expenses-related party includes clinical trial expenses of $279,402 and fees due to KMPL as Clinical Trial Manager for the Ebola Phase II clinical trial of $387,563. | | $ | 1,199,395 | | $ | — |
|